PODD
Insulet CorporationNASDAQHealthcare$204.31-1.32%ClosedMarket Cap: $14.38B
As of 2026-04-06
Valuation
P/E (TTM)
58.21
PEG
—
P/B
9.45
P/S
5.29
EV/EBITDA
30.13
DCF Value
$-28.56
FCF Yield
2.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
71.6%
Operating Margin
17.5%
Net Margin
9.1%
ROE
17.4%
ROA
7.7%
ROIC
13.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $783.8M | 72.5% | $146.3M | $101.6M | $1.44 | — |
| FY 2025 | $2.71B | 71.6% | $473.8M | $247.1M | $3.48 | — |
| Q3 2025 | $706.3M | 72.2% | $117.7M | $87.6M | $1.24 | — |
| Q2 2025 | $649.1M | 69.7% | $121.1M | $22.5M | $0.32 | — |
| Q1 2025 | $569.0M | 71.9% | $88.8M | $35.4M | $0.50 | — |
| Q4 2024 | $597.5M | 72.1% | $109.3M | $100.7M | $1.39 | — |
| FY 2024 | $2.07B | 69.8% | $308.9M | $418.3M | $5.78 | — |
| Q3 2024 | $543.9M | 69.3% | $88.1M | $77.5M | $1.08 | — |
| Q2 2024 | $488.5M | 67.7% | $54.5M | $188.6M | $2.59 | — |
| Q1 2024 | $441.7M | 69.5% | $56.9M | $51.5M | $0.73 | — |
| Q4 2023 | $509.8M | 70.9% | $106.4M | $103.3M | $1.48 | — |
| FY 2023 | $1.70B | 68.3% | $220.0M | $206.3M | $2.94 | — |